JP Morgan Chase
HZNP

JP Morgan Chase’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

JP Morgan Chase’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-150,000
Closed -$15.4M – 7904
2023
Q2 		$15.4M Buy
+150,000
New +$15.8M ﹤0.01% 1911
2021
Q4 		– Sell
-538,000
Closed -$58.9M – 7300
2021
Q3 		$58.9M Buy
+538,000
New +$55.9M 0.01% 1096

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

JP Morgan Chase's HZNP Position: Q4 2023 in Review

JP Morgan Chase sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 5,042,293 shares — an estimated $583M sold.

JP Morgan Chase first reported a position in HZNP in Q3 2013 and held it in 37 quarters. The position peaked at $1.28B in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • JP Morgan Chase reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • JP Morgan Chase sold 5,042,293 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $583M.
  • JP Morgan Chase first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 37 quarters.
  • JP Morgan Chase's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.28B in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.